London, UK – Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, acknowledges the announcement from its portfolio company Biocare Medical, regarding its acquisition of Empire Genomics.
Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridisation) instrumentation and reagents, announces the acquisition of Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics.
Empire Genomics is a premier designer, manufacturer and distributor of a comprehensive menu of clinical and custom-labeled molecular probes, enabling thousands of leading global research facilities, clinical laboratories, and biotechnology organisations to advance biomarker research, accelerate diagnoses and improve personalised treatment options for patients battling cancer and other complex diseases. Empire Genomics technology has been cited in over 500 hundred of peer-reviewed scientific publications.
“We are incredibly excited to welcome Empire Genomics to the Biocare Medical team” said Luis de Luzuriaga, CEO of Biocare Medical. “This expansion of Biocare Medical’s molecular menu combined with our advanced automation platforms such as the ONCORE Pro X will enable researchers to move faster than they ever have before; advancing cancer diagnostics more quickly for better patient outcomes.”
Empire Genomics’ innovative portfolio of molecular probes empowers thousands of leading clinical laboratories, biotechnology companies and academic institutions around the world. Since 2006, Empire Genomics has built a legacy of high quality, molecular technology and proven their ability to deliver products that improve genetic research and patient care consistently.
“The breadth of the Empire Genomics portfolio is well-suited for automation on Biocare Medical’s ONCORE Pro and ONCORE Pro X platforms to produce high-quality, reproducible FISH and CISH results.” said Jason Ramos, Vice President of Research and Development at Biocare Medical. “Combining Empire Genomics’ rapid turnaround time for new biomarker development with ONCORE Pro’s accelerated hybridization opens myriad opportunities for cancer research applications.”
Together, Biocare Medical and Empire Genomics will bring an expanded offering of solutions to those research and diagnosing cancer around the world.